Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
UNIVERSITY COLLEGE DUBLIN manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are 5 pending office actions currently active, which are assigned to 5 distinct examiners. This distribution ensures that each pending matter is handled by a different individual, providing a variety of perspectives on the university's intellectual property. The involvement of 4 distinct art units suggests that the portfolio covers several specialized fields within the biotechnology sector, requiring a broad technical understanding from the legal team.
The busiest examiner, TRAN, CHRISTINA L, is responsible for 1 pending office action. Since the total count of pending office actions is 5, the workload is spread thinly across the examining staff. This lack of concentration means that the university must manage 5 separate prosecution timelines and examiner relationships simultaneously. Practitioners should be prepared for a decentralized process where the results of one office action may not predict the outcomes of the others, as no single examiner holds a majority of the cases.
With 5 distinct examiners operating across 4 distinct art units, there is a concentration of activity within at least one art unit. This overlap requires a coordinated strategy to maintain consistency in technical arguments across the 4 distinct art units. The busiest examiner's load of 1 pending office action highlights the even distribution of the 5 total actions. This structure necessitates a comprehensive management approach to handle the diverse requirements of the different examiners and art units involved in the university's patent prosecution.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (40%) |
| §112 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, CHRISTINA L | 1 | 51.6% | +49.8% |
| KANG, TIMOTHY J | 1 | 45.5% | +27.0% |
| MINCHELLA, KAITLYN L | 1 | 26.4% | +21.7% |
| LIPPOLIS, ALEXANDRA ROSE | 1 | 47.2% | +63.6% |
| BAKSHI, PANCHAM | 1 | 76.7% | +30.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18687575 | SYSTEM AND METHOD FOR DYNAMICALLY RECOMMENDING FOOTWEAR SIZE, AND FOOTWEAR THEREOF | KANG, TIMOTHY J | — |
| 18564440 | MOLECULAR EVALUATION METHODS | MINCHELLA, KAITLYN L | — |
| 17763441 | NANOPARTICLE COMPOSITIONS FOR GENE THERAPY | LIPPOLIS, ALEXANDRA ROSE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18701230 | NUCLEIC ACID AGENTS FOR TREATMENT OF NON-SMALL-CELL LUNG CANCER | TRAN, CHRISTINA L | — |
| 18687575 | SYSTEM AND METHOD FOR DYNAMICALLY RECOMMENDING FOOTWEAR SIZE, AND FOOTWEAR THEREOF | KANG, TIMOTHY J | — |
| 18564440 | MOLECULAR EVALUATION METHODS | MINCHELLA, KAITLYN L | — |
| 17763441 | NANOPARTICLE COMPOSITIONS FOR GENE THERAPY | LIPPOLIS, ALEXANDRA ROSE | — |
| 17763509 | HYPERBRANCHED CATIONIC POLYMERS USEFUL AS NUCLEIC ACID DELIVERY VECTORS FOR TRANSFECTING CELLS | BAKSHI, PANCHAM | — |
| Art Unit | Apps |
|---|---|
| 1637 | 2 |
| 3689 | 1 |
| 1685 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18701230 | NUCLEIC ACID AGENTS FOR TREATMENT OF NON-SMALL-CELL LUNG CANCER | TRAN, CHRISTINA L | 1637 | §112 | Non-Final OA | — | Pending | Apr 14, 2024 |
| 18687575 | SYSTEM AND METHOD FOR DYNAMICALLY RECOMMENDING FOOTWEAR SIZE, AND FOOTWEAR THEREOF | KANG, TIMOTHY J | 3689 | §101§102 | Final Rejection | — | Pending | Feb 28, 2024 |
| 18564440 | MOLECULAR EVALUATION METHODS | MINCHELLA, KAITLYN L | 1685 | §101§112 | Non-Final OA | — | Pending | Nov 27, 2023 |
| 17763441 | NANOPARTICLE COMPOSITIONS FOR GENE THERAPY | LIPPOLIS, ALEXANDRA ROSE | 1637 | §102§103§112 | Non-Final OA | — | Pending | Mar 24, 2022 |
| 17763509 | HYPERBRANCHED CATIONIC POLYMERS USEFUL AS NUCLEIC ACID DELIVERY VECTORS FOR TRANSFECTING CELLS | BAKSHI, PANCHAM | 1623 | §103DP | Non-Final OA | — | Pending | Mar 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITY COLLEGE DUBLIN has 5 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
Christina L Tran has the most, with 1 of UNIVERSITY COLLEGE DUBLIN's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
